Hi Kelvin - many thanks for that detailed reply and the link to your interview with Dr Lapp, which was fascinating. It sounds very hopeful that Ampligen might get FDA approval relatively soon; what that means for us in the UK, I don't know. That's an interesting point you make about negative stories about Ampligen coming from short-traders. When I was googling for XMRV in the early months after the Science study, some of the hits I got were to a Yahoo! stock traders message board and they were talking about Ampligen in the context of XMRV. Even knowing nothing about stock trading, it seemed clear to me that some of the stuff that was being said (not just about Ampligen, but XMRV and CFS) was just beyond ridiculous and appeared to be just a strategy to prevent others investing (I have no XMRV axe to grind but it was just wildy inaccurate). There was also a lot of very negative stuff about how Hemispherx have behaved as a company, which I couldn't judge but which I think I may also have seen on PR so it might have some basis. We have to remember that not everyone cares about other people, just money - as opposed to Dr Lapp, who seems from your interview with him to be the very opposite! That's interesting that you spoke to so many people about their Ampligen experience. I wonder if anyone has done a systematic long-term follow-up study.